Fate’s off-the-shelf CAR-T therapy shows early promise in treatment-resistant autoimmune disease on July 09, 2026 Allogeneic Allogeneic Anti-CD19 1XX-CAR T-cells FT819 Autoimmune Diseases Automobiles B-Lymphocytes Depletion Encephalitis, St. Louis FT839 Identifier Lupus Erythematosus, Systemic Lupus Nephritis Phase 1/II RMAT +
AstraZeneca's Saphnelo Succeeds in Phase III as Self-Injectable Lupus Treatment on September 18, 2025 anifrolumab AstraZeneca Clinical Trials disease activity Encephalitis, St. Louis Lupus Erythematosus, Systemic Phase III Saphnelo Self-Injectable subcutaneous TULIP-SC trial +